WALTHAM, Mass .– (BUSINESS WIRE) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today published the most comprehensive descriptive analysis of adult T1D patients with and without diabetic ketoacidosis (DKA) treated with insulin management software. The results of the study, presented at the American Diabetes Association’s 81st Annual Scientific Sessions, demonstrated that a standard continuous insulin infusion (CII) process was managed using Glucommander ™ IV, Glytec’s eGlycemic Management System (eGMS®) , Patient safely in a predefined target area with minimal hypoglycaemia rates.
“The optimal treatment regimen for patients with type 1 diabetes in the hospital is unknown. The general consensus is that patients with type 1 diabetes are at high risk of hypoglycemia when treated with intensive insulin therapy, ”said Priyathama Vellanki, MD, study co-author, medical director of the Grady Endocrinology Clinic and assistant professor of medicine . Faculty of Medicine, Department of Endocrinology, Emory University School of Medicine. “The data show that hypoglycaemia rates are extremely low when treated with Glucommander. This is a very encouraging finding for people living with T1D and the hospital doctors who care for them. ”
The analysis is based on patient data from 2015 to 2020, which were extracted from 154 hospitals in 17 countries via the national Glytec® Inpatient Database. In total, it includes data from more than 15,000 T1D patients, 4,592 with DKA and 10,886 without DKA, all of whom were treated with Glucommander IV. In patients with DKA, the rates of moderate hypoglycemia (defined as blood glucose <70 mg / dL) were 0.588%. In subjects with severe hypoglycaemia (defined as BG <40 mg / dL), the hypoglycaemia rate was 0.015%. Compared to previous studies in hospitalized DKA patients that were on paper logs and were not treated with Glucommander, these results show that Glucommander can reduce the incidence of hypoglycaemia five-fold and the episodes of severe hypoglycaemia by almost ten-fold. In this analysis, the rates of severe and moderate hypoglycaemia in patients without DKA were 0.030% and 0.877%, respectively. The time to target BG range was 7.8 hours for DKA patients and 7.1 hours for patients without DKA.
eGMS shows low rates of hypoglycaemia in patients with kidney disease
In a separate poster that will be presented at the ADA scientific sessions, Glytec will showcase additional research on the use of eGMS to control blood sugar levels in patients with kidney disease. Patients with chronic kidney disease and acute kidney damage require special attention when receiving insulin in the hospital due to high rates of hypoglycaemia. Using Glucommander’s proprietary non-linear IV infusion software and an appropriate order set, the data demonstrated that patients with renal impairment had low rates of hypoglycemia and acceptable glycemic control.
The study analyzed 13,775 intensive care patients in the national Glytec database between 2017 and 2021 with eGFR<60 ml/min/1.73 m2 and with at least two blood glucose values >180 mg / dl. This research shows that renal failure patients treated with Glucommander IV to administer IV insulin (following the introductory recommendations for renal failure set in the order) were more consistent in the BG target range and had lower hypoglycemia rates compared to published data from other electronic devices Blood sugar management tools were lying.
The American Diabetes Association’s 81st Annual Scientific Sessions will be held virtually June 25-29, 2001. Further information can be found at: https://professional.diabetes.org/scientific-sessions.
Further information and the analysis of T1D patients with and without DKA can be found at: https://glytecsystems.com/evidence/glycemic-outcomes-for-adult-type-1-diabetes-t1d-with-and-without- dka .
Further information and the analysis of patients with kidney disease can be found at: https://glytecsystems.com/evidence/iv-insulin-via-glucommander-eglycemic-management-system-egms-demonstrates-low-rates-of- hypoglycemia-bei -Patients-with-low-EGFR-versus-other-electronic-glycemic-management-tools.
About Glytec
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. FDA-cleared titration software and proprietary algorithms are the only solution capable of providing personalized recommendations for diabetes management across the care continuum from hospital to home. With continued support from its team of doctors, nurses, and technologists headquartered outside of Boston, Glytec is improving outcomes and controlling costs for the large population of patients in need of insulin treatment – including those with and without a diagnosis of diabetes. For more information, follow Glytec on Twitter (@Glytec) and LinkedIn or visit www.GlytecSystems.com.
MAR-0000347 Rev 1.0
